Samil Pharmaceutical announced its preliminary performance on the 3rd, achieving consolidated sales of 219.8 billion KRW and operating profit of 200 million KRW last year.
Consolidated sales grew by 11.9% compared to the previous year, while operating profit decreased by 97.3%. The sales figure marked the highest performance in the company's history.
Samil Pharmaceutical has recently achieved record-high sales every year since its founding. The increase in sales is attributed to steady growth of existing product lineups such as ‘Libact’ and ‘Libidi’, as well as newly launched products like ‘Rebakei’ and ‘Apillibu’. By business division, the Ophthalmology Sales Headquarters and CNS (Central Nervous System) Sales Headquarters continue to show strong growth. Among these, ‘Apillibu’, a biosimilar of Eylea developed by Samsung Bioepis, recorded a surprising 1 billion KRW in sales in its first month after launching in May last year and continues to grow steadily.
The rapidly growing Ophthalmology Sales Headquarters achieved cumulative sales of 67.2 billion KRW, marking a 34.4% growth compared to the same period last year, while the CNS Sales Headquarters also achieved cumulative sales of 36.5 billion KRW, showing a 30.4% growth compared to the previous year.
Samil Pharmaceutical’s CNS division recorded sales of 6.7 billion KRW in 2021. However, since the second half of 2021, after forming a dedicated sales team and continuously expanding new psychiatric drug lineups including Viatris and Sandoz, the division posted sales of 21.1 billion KRW in 2022, 28 billion KRW in 2023, and 36.5 billion KRW in 2024, maintaining rapid growth.
A company representative explained, “On a separate basis, both sales and operating profit have shown steady growth, but the consolidated results reflect the subsidiary performance of the Vietnam manufacturing corporation, which is pursuing a global CMO business. The Vietnam corporation is currently in the preparation phase for commercial production, incurring labor and operating costs, and the resulting increase in selling and administrative expenses has led to a decrease in consolidated results.”
The representative added, “Meaningful performance achievements are expected this year as well, driven by continuous growth of key products, growth of new products such as ‘Rebakei’ and ‘Apillibu’, and the rapid growth trends of the Ophthalmology and CNS divisions.”
Meanwhile, in October last year, Samil Pharmaceutical officially signed a CMO (Contract Manufacturing Organization) agreement with Formosa, a listed pharmaceutical company in Taiwan, for the ophthalmic drug 'APP 13007'. 'APP 13007' is an eye drop developed by Formosa that received approval from the U.S. Food and Drug Administration (FDA) in March last year for relieving pain and inflammation after eye surgery. Since the contract with Formosa, Samil Pharmaceutical has been continuously discussing CMO contracts with global pharmaceutical companies.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
